Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc (AGEN) is a clinical-stage biotechnology company pioneering novel immunotherapies to combat cancer and infectious diseases. This page provides centralized access to official press releases, financial updates, and scientific developments from Agenus, offering stakeholders a reliable resource for tracking the company’s progress.
Investors and researchers will find timely updates on clinical trial milestones, regulatory filings, and strategic partnerships, alongside analyses of AGEN’s proprietary platforms like Retrocyte Display™ antibody technology. The curated news collection enables efficient monitoring of the company’s immuno-oncology pipeline and manufacturing advancements through its integrated cGMP facilities.
Key categories include earnings reports, therapy development updates, licensing agreements, and peer-reviewed research highlights. Bookmark this page to stay informed about AGEN’s innovations in checkpoint modulators, cell therapies, and vaccine adjuvants without navigating multiple sources.
Agenus (NASDAQ: AGEN) has announced two upcoming presentations featuring BOT/BAL at the AACR IO Annual Meeting in Los Angeles from February 23-26. The first presentation will showcase interim data from a Phase 2 study combining botensilimab and balstilimab (BOT/BAL) with MiNK Therapeutics' iNKT cell therapy, AgenT-797, in patients with refractory gastric cancer.
The second presentation, a Trial-in-Progress poster, will focus on data from an ongoing Phase 1/2 study of BOT/BAL in first-line MSS colorectal cancer. The presentations are scheduled for Monday, February 24th, with the poster session running from 1:45-4:45 p.m. PST and the biomarker analysis presentation from 1:39-1:45 p.m. PST.
Agenus (NASDAQ: AGEN) published results in the Journal of Clinical Oncology from its study of botensilimab (BOT) combined with balstilimab (BAL) in patients with relapsed/refractory metastatic sarcomas. The Phase 1 trial demonstrated significant efficacy across multiple sarcoma subtypes, including traditionally resistant forms.
Key results include an overall response rate of 19.2% in the study population (n=52), with 27.8% response rate in angiosarcoma patients (n=18). The disease control rate reached 65.4%, with 4.4 months median progression-free survival. The treatment showed a remarkable median duration of response of 21.7 months and 69% overall survival rate at 12 months.
The combination therapy demonstrated a manageable safety profile, with diarrhea/colitis (grade 3, 6.3%) as the most common treatment-related adverse event, effectively managed with steroids and TNF-alpha inhibitors. No Grade 4 or 5 adverse events were reported.
Agenus (NASDAQ: AGEN) presented new data on botensilimab (BOT) and balstilimab (BAL) combination therapy at ASCO GI, demonstrating significant potential in colorectal cancer (CRC) treatment. The data comes from multiple studies involving over 1,100 patients across 60+ centers worldwide.
Key findings include results from two neoadjuvant studies (UNICORN and NEST) with 80+ patients, showing promising pathological complete response rates: 93% in dMMR/MSI-H tumors and 29% in pMMR/MSS tumors. In first-line treatment, the combination with FOLFOX-Bevacizumab achieved 71% overall response rate in 14 patients.
A global Phase 2 study with 234 patients demonstrated 19% overall response rate and 55% disease control rate in refractory MSS mCRC, with 70% of responses ongoing at data cut-off. The therapy showed particular promise in treating microsatellite stable (MSS) CRC tumors, which represent 85-95% of CRC cases and typically don't respond to immunotherapy.
Agenus (NASDAQ: AGEN) announced five presentations featuring botensilimab (BOT) plus balstilimab (BAL) at the upcoming ASCO GI Symposium (January 23-25, 2025). The presentations will showcase BOT/BAL's activity across three distinct colorectal cancer settings: late-line metastatic, first-line, and neoadjuvant treatment.
The studies demonstrate BOT/BAL's consistent activity in microsatellite stable (MSS) colorectal cancer, which represents over 80% of CRC cases with treatment options, as well as microsatellite instability-high (MSI-H) CRC. An additional presentation will feature BOT/BAL and invariant natural killer T cells (iNKTs) in refractory gastric cancer patients.
Agenus announced a strategic realignment focusing on its lead botensilimab/balstilimab (BOT/BAL) program, which has shown clinical activity in various cancers including microsatellite stable colorectal cancer. The company aims to reduce annual expenditures by 60% and achieve a cash burn of $100 million for FY 2025.
The restructuring follows a $22 million mortgage secured by real estate assets. Key measures include staff reductions, operational adjustments, and transitioning biologics CMC capabilities to a fee-for-service model. The company will provide transition support to affected employees while maintaining focus on advancing BOT/BAL for patients with treatment options.
Agenus (NASDAQ: AGEN) has secured a $22 million mortgage backed by its Berkeley and Vacaville properties, providing $20 million in net proceeds. The two-year mortgage includes interest payable 50% in cash and 50% in common stock, at rates of 12% for Year 1 and 13% for Year 2. The company announced a Strategic Operational Realignment Plan focusing on botensilimab/balstilimab (BOT/BAL) in MSS colorectal cancer, targeting a 60% reduction in annual external expenditures. The plan includes transforming CMC capabilities into a fee-for-service biologics manufacturing business, aiming to reduce FY 2025 cash burn to approximately $100 million.
Agenus (AGEN) reported Q3 2024 financial results and provided updates on BOT/BAL development. The company ended Q3 with $44.8 million in cash, down from $76.1 million in December 2023. Revenue was $25.1 million for Q3 2024, compared to $24.3 million in Q3 2023. Net loss was $67.2 million for Q3 2024. BOT/BAL showed promising clinical progress in MSS colorectal cancer and sarcomas. The company is pursuing strategic initiatives including asset monetization and operational efficiencies to strengthen its financial position. Cash used in operations decreased to $129.7 million for the first nine months of 2024, down from $183.8 million in the same period of 2023.
Agenus (NASDAQ: AGEN) will present new data on two promising immunotherapy candidates at the SITC 2024 Annual Meeting in Houston. The presentations will feature botensilimab, an Fc-enhanced anti-CTLA-4 antibody showing efficacy in treatment-resistant cancers, and AGEN1721, a first-in-class bifunctional antibody targeting FAP and TGFβ.
Botensilimab enhances both innate and adaptive immunity, demonstrating effectiveness in glioblastoma, melanoma, colorectal, pancreatic, and breast cancers. AGEN1721 works by remodeling the tumor microenvironment, depleting cancer-associated fibroblasts, and neutralizing TGFβ's immunosuppressive effects, transforming cold tumors into immune-responsive environments.
Agenus (NASDAQ: AGEN), a company focused on developing immunological cancer treatments, has scheduled its third quarter 2024 financial results release before market opening on Tuesday, November 12th, 2024. The company will host a conference call and webcast at 8:30 a.m. ET the same day, featuring executive discussions of the results and a corporate update.
GSK announced positive topline data from a phase 3 trial evaluating the co-administration of AREXVY (RSV vaccine) and SHINGRIX (shingles vaccine) in adults 50 years and older. The study met its primary endpoint, showing a non-inferior immune response when the vaccines were given together compared to separate administration. Co-administration was well-tolerated with acceptable safety profiles.
Key findings include:
- Comparable immune responses in co-administration and separate administration groups
- Most common adverse events: injection site pain, fatigue, and myalgia
- Similar duration of adverse events across groups
GSK plans to submit these results to support regulatory submissions to the FDA, EMA, and other regulators. The company aims to reduce barriers to adult immunization by potentially decreasing the number of healthcare visits required for vaccination.
